Cargando…
High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection
SARS-CoV-2 nucleocapsid protein (NP) is the main target for COVID-19-diagnostic PCR and antigen rapid diagnostic tests (Ag-RDTs). Ag-RDTs are more convenient than PCR tests for point-of-care testing or self-testing to identify the SARS-CoV-2 antigen. The sensitivity and specificity of this method de...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279465/ https://www.ncbi.nlm.nih.gov/pubmed/37379800 http://dx.doi.org/10.1016/j.bbrc.2023.06.067 |
_version_ | 1785060598608822272 |
---|---|
author | Fujisawa, Mizuki Adachi, Yu Onodera, Taishi Shiwa-Sudo, Nozomi Iwata-Yoshikawa, Naoko Nagata, Noriyo Suzuki, Tadaki Takeoka, Shinji Takahashi, Yoshimasa |
author_facet | Fujisawa, Mizuki Adachi, Yu Onodera, Taishi Shiwa-Sudo, Nozomi Iwata-Yoshikawa, Naoko Nagata, Noriyo Suzuki, Tadaki Takeoka, Shinji Takahashi, Yoshimasa |
author_sort | Fujisawa, Mizuki |
collection | PubMed |
description | SARS-CoV-2 nucleocapsid protein (NP) is the main target for COVID-19-diagnostic PCR and antigen rapid diagnostic tests (Ag-RDTs). Ag-RDTs are more convenient than PCR tests for point-of-care testing or self-testing to identify the SARS-CoV-2 antigen. The sensitivity and specificity of this method depends mainly on the affinity and specificity of NP-binding antibodies; therefore, antigen-antibody binding is key elements for the Ag-RDTs. Here, we applied the high-throughput antibody isolation platform that has been utilized to isolate therapeutic antibodies against rare epitopes. Two NP antibodies were identified to recognize non-overlapping epitopes with high affinity. One antibody specifically binds to SARS-CoV-2 NP, and the other rapidly and tightly binds to SARS-CoV-2 NP with cross-reactivity to SARS-CoV NP. Furthermore, these antibodies were compatible with a sandwich enzyme-linked immunosorbent assay that exhibited enhanced sensitivity for NP detection compared to the previously isolated NP antibodies. Thus, the NP antibody pair is applicable to more sensitive and specific Ag-RDTs, highlighting the utility of a high-throughput antibody isolation platform for diagnostics development. |
format | Online Article Text |
id | pubmed-10279465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102794652023-06-21 High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection Fujisawa, Mizuki Adachi, Yu Onodera, Taishi Shiwa-Sudo, Nozomi Iwata-Yoshikawa, Naoko Nagata, Noriyo Suzuki, Tadaki Takeoka, Shinji Takahashi, Yoshimasa Biochem Biophys Res Commun Article SARS-CoV-2 nucleocapsid protein (NP) is the main target for COVID-19-diagnostic PCR and antigen rapid diagnostic tests (Ag-RDTs). Ag-RDTs are more convenient than PCR tests for point-of-care testing or self-testing to identify the SARS-CoV-2 antigen. The sensitivity and specificity of this method depends mainly on the affinity and specificity of NP-binding antibodies; therefore, antigen-antibody binding is key elements for the Ag-RDTs. Here, we applied the high-throughput antibody isolation platform that has been utilized to isolate therapeutic antibodies against rare epitopes. Two NP antibodies were identified to recognize non-overlapping epitopes with high affinity. One antibody specifically binds to SARS-CoV-2 NP, and the other rapidly and tightly binds to SARS-CoV-2 NP with cross-reactivity to SARS-CoV NP. Furthermore, these antibodies were compatible with a sandwich enzyme-linked immunosorbent assay that exhibited enhanced sensitivity for NP detection compared to the previously isolated NP antibodies. Thus, the NP antibody pair is applicable to more sensitive and specific Ag-RDTs, highlighting the utility of a high-throughput antibody isolation platform for diagnostics development. Elsevier Inc. 2023-09-17 2023-06-19 /pmc/articles/PMC10279465/ /pubmed/37379800 http://dx.doi.org/10.1016/j.bbrc.2023.06.067 Text en © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Fujisawa, Mizuki Adachi, Yu Onodera, Taishi Shiwa-Sudo, Nozomi Iwata-Yoshikawa, Naoko Nagata, Noriyo Suzuki, Tadaki Takeoka, Shinji Takahashi, Yoshimasa High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection |
title | High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection |
title_full | High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection |
title_fullStr | High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection |
title_full_unstemmed | High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection |
title_short | High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection |
title_sort | high-throughput isolation of sars-cov-2 nucleocapsid antibodies for improved antigen detection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279465/ https://www.ncbi.nlm.nih.gov/pubmed/37379800 http://dx.doi.org/10.1016/j.bbrc.2023.06.067 |
work_keys_str_mv | AT fujisawamizuki highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection AT adachiyu highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection AT onoderataishi highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection AT shiwasudonozomi highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection AT iwatayoshikawanaoko highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection AT nagatanoriyo highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection AT suzukitadaki highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection AT takeokashinji highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection AT takahashiyoshimasa highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection |